Efficacy and safety of first-line EGFR-TKI combined with chemotherapy versus EGFR-TKI monotherapy in patients with EGFR-mutant non-small cell lung cancer and liver metastases: A propensity score-matched analysis.

Abstract excerpt

INTRODUCTION: Liver metastasis (LM) confers a poor prognosis in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Although EGFR tyrosine kinase inhibitors (TKIs) are the standard first-line treatment, the optimal approach for this high-risk subgroup remains uncertain. This study compared the efficacy and safety of EGFR-TKI monotherapy versus EGFR-TKI combined with...

Topics

Join the communities discussing this publication.

• Aged
• Antineoplastic Combined Chemotherapy Protocols
• Carcinoma, Non-Small-Cell Lung
• ErbB Receptors